ABLIVA AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.19 SEK | -0.94% |
|
+13.50% | -22.61% |
| Feb. 23 | Abliva AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
| 2023 | Abliva AB Reaches Patient Enrollment Goal for Wave 1 of the FALCON Study | CI |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | - | Sales 2025 * | - | Capitalization | 237M 21.84M |
|---|---|---|---|---|---|
| Net income 2024 * | -142M -13.1M | Net income 2025 * | -157M -14.48M | EV / Sales 2024 * | - |
| Net cash position 2024 * | 124M 11.44M | Net cash position 2025 * | 173M 15.96M | EV / Sales 2025 * | - |
| P/E ratio 2024 * |
-1.46
x | P/E ratio 2025 * |
-1.27
x | Employees | 7 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.06% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | -0.94% | ||
| 1 week | +13.50% | ||
| Current month | +10.47% | ||
| 1 month | +18.45% | ||
| 3 months | -19.32% | ||
| 6 months | -12.04% | ||
| Current year | -22.61% |
1 week
0.17
0.21
1 month
0.150.21
Current year
0.140.27
1 year
0.140.32
3 years
0.140.77
5 years
0.142.68
10 years
0.1482.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ellen Donnelly
CEO | Chief Executive Officer | 50 | 21-02-02 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Director of Finance/CFO | 57 | 13-11-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chairman | 69 | 16-04-27 | |
David Bejker
BRD | Director/Board Member | 49 | 17-04-26 |
Eskil Elmér
FOU | Founder | 54 | 00-01-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-10 | 0.19 | -0.94% | 1,402,478 |
| 24-05-08 | 0.1918 | +5.62% | 1,659,506 |
| 24-05-07 | 0.1816 | +1.23% | 1,128,211 |
| 24-05-06 | 0.1794 | +7.17% | 1,776,130 |
| 24-05-03 | 0.1674 | -1.99% | 600,733 |
Delayed Quote Nasdaq Stockholm, May 10, 2024 at 11:29 am EDT
More quotes
Abliva AB is a Sweden-based company involved in pharmaceutical industry. The Company focuses on the development of novel treatments for primary mitochondrial diseases.
Calendar
2024-05-20
- Q1 2024 Earnings Release (Projected)
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -22.61% | 21.85M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- ABLI Stock